Compare IGR & INMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IGR | INMD |
|---|---|---|
| Founded | 2004 | 2008 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 719.1M | 842.0M |
| IPO Year | N/A | 2018 |
| Metric | IGR | INMD |
|---|---|---|
| Price | $4.71 | $15.31 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $17.33 |
| AVG Volume (30 Days) | 476.7K | ★ 597.4K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 13.93% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.74 |
| Revenue Next Year | N/A | $3.26 |
| P/E Ratio | ★ N/A | $10.11 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.15 | $12.72 |
| 52 Week High | $5.28 | $16.74 |
| Indicator | IGR | INMD |
|---|---|---|
| Relative Strength Index (RSI) | 51.54 | 52.71 |
| Support Level | $4.61 | $14.94 |
| Resistance Level | $4.69 | $15.23 |
| Average True Range (ATR) | 0.07 | 0.25 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 54.55 | 27.27 |
CBRE Clarion Global Real Estate Income Fund is a United States-based diversified, closed-end management investment company. Its primary objective is high current income, and its secondary objective is capital appreciation. The fund invests a majority of its total assets in income-producing real estate securities, which includes common stocks, preferred securities, warrants, and convertible securities issued by real estate companies, such as real estate investment trusts. Under normal market conditions, it invests in real estate equity securities of companies domiciled predominantly in developed countries.
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8, among others. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia, Israel, and other regions.